Shi-Yi Wang, MD, PhD
Senior Research Scientist in EpidemiologyDownloadHi-Res Photo
Cards
Contact Info
About
Copy Link
Titles
Senior Research Scientist in Epidemiology
Biography
Dr. Wang is an Associate Professor at the Yale School of Public Health, faculty member of Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, and faculty member of Public Health Modeling Concentration, Yale School of Public Health. His primary interests focus on outcomes research and decision science. He is interested in combining systematic literature reviews, secondary data analyses, and simulation modeling to examine issues that are critical to clinicians and policy makers’ decision making. He has been working on several breast cancer projects, including an evaluation of preoperative breast MRI, development of an individualized decision aid to help radiotherapy decision-making, and assessment of sentinel lymph node biopsy for patients with ductal carcinoma in situ. He is also evaluating end-of-life care quality. He has served as the primary investigator or co-investigator in several projects (funded by Yale Cancer Center, AHRQ, NCI, ACS, and PCORI).
Last Updated on April 07, 2025.
Appointments
Chronic Disease Epidemiology
Senior Research ScientistPrimaryChronic Disease Epidemiology
LecturerSecondary
Other Departments & Organizations
Education & Training
- PhD
- University of Minnesota (2012)
- MD
- Taipei Medical College (1992)
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Terminal Care
Public Health Interests
Health Care Quality, Efficiency; Modeling; Global Health; Aging; End-of-life Care; Cancer
ORCID
0000-0002-3294-5784
Research at a Glance
Yale Co-Authors
Frequent collaborators of Shi-Yi Wang's published research.
Publications Timeline
A big-picture view of Shi-Yi Wang's research output by year.
Research Interests
Research topics Shi-Yi Wang is interested in exploring.
Cary P Gross, MD
Xiaomei Ma, PhD
Michael S. Leapman, MD, MHS
Sarah Westvold, MPH
Michaela Dinan, PhD
Natalia Kunst, PhD
124Publications
3,758Citations
Breast Neoplasms
Terminal Care
Publications
2026
Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population
Wang M, Sigel B, Liu L, Huber J, Ji M, Schoen M, Sanfilippo K, Thomas T, Colditz G, Hsu S, Wang S, Chang S. Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population. International Journal Of Cancer 2026 PMID: 41813601, PMCID: PMC13004480, DOI: 10.1002/ijc.70412.Peer-Reviewed Original ResearchAltmetricConceptsMultiple myelomaRisk factorsContribution of modifiable risk factorsVeteran populationVeterans Health AdministrationPopulation attributable fractionModifiable risk factorsExcess body mass indexProgression of MGUS to multiple myelomaMGUS to multiple myelomaBody mass indexPlasma cell dyscrasiaRisk of deathAttributable fractionAgent Orange exposureProgressive burdenRetrospective cohort studyHealth AdministrationWeight managementPotential intervention strategiesUnited States veteran populationLifestyle modificationPrevention strategiesCohort studyGeneral populationThe association between body fatness and prevalent MGUS in the U.S. general population
Ji M, Huber J, Wang M, Lan T, Colditz G, Wang S, Chang S. The association between body fatness and prevalent MGUS in the U.S. general population. Cancer Epidemiology 2026, 101: 103021. PMID: 41702266, DOI: 10.1016/j.canep.2026.103021.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsDual-energy X-ray absorptiometryObesity markersBioelectrical impedance analysisNHANES IIIConfidence intervalsBody fat percentageU.S. general populationFat-free massMultivariate logistic regression analysisLogistic regression analysisContinuous NHANESDual-energy X-ray absorptiometry measurementsNational HealthBaseline BMINHANESOdds ratioFat percentageX-ray absorptiometryU.S. populationGeneral populationBody fatLogistic regressionBody compositionOddsTetrapolar bioelectrical impedance analysisA Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling.
Wang X, Long J, Rothen J, Huang S, Soulos P, Goldberg S, Robinson T, Ma S, Mamtani R, Presley C, Wang S, Kunst N, Gross C, Dinan M. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal Of The National Comprehensive Cancer Network 2026, 24 PMID: 41698347, DOI: 10.6004/jnccn.2025.7131.Peer-Reviewed Original ResearchThis study introduces Y-MATRIX, a taxonomy classifying genomic profiling results by clinical actionability, showing increased actionable findings in advanced lung cancer from 2017 to 2023.Overestimation of multiple myeloma survival from cancer registry data
Huber J, Wang M, Wang R, Schoen M, Colditz G, Wang S, Chang S. Overestimation of multiple myeloma survival from cancer registry data. Journal Of The National Cancer Institute 2026, djag028. PMID: 41652897, PMCID: PMC12967285, DOI: 10.1093/jnci/djag028.Peer-Reviewed Original ResearchAltmetricConceptsSymptomatic MMMultiple myelomaFive-year relative survival estimatesSurvival statisticsCancer registry dataRelative survival estimatesMM managementPremalignant conditionSurveillance, EpidemiologyMultiple myeloma survivalRegistry dataMedian survivalMM survivalMyeloma survivalSEERPopulation levelSurvival estimatesSurvivalMyelomaMonthsStatisticallyInclusionEpidemiologyPatientsAdoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. JCO Oncology Practice 2026, op2500617. PMID: 41632928, DOI: 10.1200/op-25-00617.Peer-Reviewed Original ResearchAltmetricConceptsProstate-specific membrane antigen positron emission tomographyPSMA-PETProstate cancerPositron emission tomographyPET imagingNational utilization patternsIncident prostate cancer casesLong-term clinical benefitPSMA PET imagingEmission tomographyProstate cancer casesEvidence of diagnostic accuracyCross-sectional studyClinical benefitCancer casesEligible patientsDiagnostic accuracyProstateInsurance beneficiariesCancerClinical practiceHealth care characteristicsProportion of individualsAdministrative claimsTomographySmoldering multiple myeloma in the United States: a population-based analysis
Wang S, Wang R, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff A, Chang S. Smoldering multiple myeloma in the United States: a population-based analysis. Blood Advances 2026, 10: 661-664. PMID: 41213002, PMCID: PMC12870838, DOI: 10.1182/bloodadvances.2025017817.Peer-Reviewed Original ResearchAltmetricTrends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022
Wang R, Davidoff A, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Chang S, Wang S. Trends in Smoldering Myeloma Incidence in the United States From Cancer Registries, 2012–2022. American Journal Of Hematology 2026, 101: 923-925. PMID: 41528052, PMCID: PMC12912868, DOI: 10.1002/ajh.70202.Peer-Reviewed Original ResearchAltmetricRisk of late recurrence of colorectal and breast cancer among older long-term cancer survivors
Yasin F, Westvold S, Long J, Hyslop T, Cecchini M, Leeds I, Silber A, Wang S, Spees L, Forman R, Kwaramba T, Taylor M, Gross C, Dinan M. Risk of late recurrence of colorectal and breast cancer among older long-term cancer survivors. JNCI Cancer Spectrum 2026, pkag002. PMID: 41499446, DOI: 10.1093/jncics/pkag002.Peer-Reviewed Original ResearchConceptsRectal cancer survivorsCancer survivorsPost-diagnosisOlder long-term cancer survivorsStage I-III breastLong-term cancer survivorsYears post-diagnosisAbsolute risk differenceCancer-specific mortalityOther-cause mortalityRetrospective cohort studyMedicare claimsER-positive diseaseSEER-MedicareCancer diagnosisCohort studyRisk differenceRectal cancerYears post-treatmentSurvivorsBreast cancerLate recurrenceTreat recurrenceCumulative incidenceBreast
2025
Personalized risk assessment of frailty in long-term cancer survivors
Forman R, Westvold S, Long J, Fan J, Hyslop T, Conlin K, Jacobson S, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Presley C, Yasin F, Taylor M, Kwaramba T, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of frailty in long-term cancer survivors. Journal Of Geriatric Oncology 2025, 17: 102804. PMID: 41319472, DOI: 10.1016/j.jgo.2025.102804.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsFrailty indexPersonalized risk assessmentDelivery of survivorship careStage I-III breastCancer diagnosisLong-term cancer survivorsCancer survivor populationAssessment of frailtyClinical prediction ruleSurvivorship careFive-year survivorsCancer survivorsSurvivor populationFrailty progressionPost-diagnosisMedicare dataRisk stratification toolHigh-risk groupRestricted mean survival timeFrailtyEnd ResultsSignificant predictorsLong-term survivorsSurvivorsStratification toolRisk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer
Taylor M, Westvold S, Long J, Hyslop T, Silber A, Forman R, Yasin F, Kwaramba T, Wang S, Leapman M, Cecchini M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Risk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer. JAMA Network Open 2025, 8: e2544812. PMID: 41296485, PMCID: PMC12658655, DOI: 10.1001/jamanetworkopen.2025.44812.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSurvivors of breastLate-onset depressionCancer survivorsAssociated with greater hazardCohort studyLong-term survivors of breastDual eligiblesColorectal cancerMedicare-Medicaid dual eligibilityCancer diagnosisLong-term cancer survivorsColorectal cancer survivorsFee-for-service MedicareBreast cancer survivorsComorbidity burdenProstate cancer survivorsPrevalence of depressionRisk of depressionFollow-up careMedicaid dual eligibilityFee-for-serviceDiagnosis of anxietyRisk factorsLow-risk tertileAssociated with greater risk
Academic Achievements & Community Involvement
Copy Link
Honors
honor The Population Science Research Prize
01/31/2017Other AwardYale Cancer CenterDetailsUnited Stateshonor The Distinguished Student Mentor Award
06/30/2016Other AwardYale School of Public HealthDetailsUnited States
News
Copy Link
News
- May 06, 2025
Genetic Test Underused in Cancer Care
- August 07, 2023
Screening Mammograms Carry Risks for Older Women, Study Finds
- May 05, 2023
Becca Levy and the Fight Against Ageism
- March 05, 2023
Improving Care of Patients Receiving Advanced Cancer Treatment
Get In Touch
Copy Link
Contacts
Email
Academic Office Number
Locations
60 College Street
Academic Office
Ste 432
New Haven, CT 06510